138 related articles for article (PubMed ID: 12746649)
21. The effect of calcitriol and its analogues on proliferation and hormone expression in cultured cells of thyroid medullary carcinomas.
Zabel M; Flig K; Gebarowska E; Surdyk-Zasada J
Folia Morphol (Warsz); 2003 Nov; 62(4):463-5. PubMed ID: 14655142
[TBL] [Abstract][Full Text] [Related]
22. [New developments in the treatment of medullary thyroid carcinoma].
Vitale G; Cascone E; Lupoli G; Ciccarelli A; Barone C; Lupoli G
Minerva Endocrinol; 1998 Dec; 23(4):121-8. PubMed ID: 10361810
[TBL] [Abstract][Full Text] [Related]
23. Medullary thyroid cancer.
You YN; Lakhani V; Wells SA; Moley JF
Surg Oncol Clin N Am; 2006 Jul; 15(3):639-60. PubMed ID: 16882502
[TBL] [Abstract][Full Text] [Related]
24. [Immuno-histochemical study of medullary thyroid carcinoma].
Bessho T
Nihon Geka Gakkai Zasshi; 1987 Jul; 88(7):872-84. PubMed ID: 2890090
[TBL] [Abstract][Full Text] [Related]
25. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line.
Quidville V; Segond N; Lausson S; Frenkian M; Cohen R; Jullienne A
Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):14-30. PubMed ID: 16997128
[TBL] [Abstract][Full Text] [Related]
26. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
[TBL] [Abstract][Full Text] [Related]
27. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature.
Bhanot P; Yang J; Schnadig VJ; Logroño R
Diagn Cytopathol; 2007 May; 35(5):285-92. PubMed ID: 17427218
[TBL] [Abstract][Full Text] [Related]
28. Medullary thyroid cancer: therapeutic targets and molecular markers.
Ball DW
Curr Opin Oncol; 2007 Jan; 19(1):18-23. PubMed ID: 17133107
[TBL] [Abstract][Full Text] [Related]
29. Long-term prognosis of medullary thyroid carcinoma.
Rendl G; Manzl M; Hitzl W; Sungler P; Pirich C
Clin Endocrinol (Oxf); 2008 Sep; 69(3):497-505. PubMed ID: 18331612
[TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide.
Lupoli G; Cascone E; Arlotta F; Vitale G; Celentano L; Salvatore M; Lombardi G
Cancer; 1996 Sep; 78(5):1114-8. PubMed ID: 8780551
[TBL] [Abstract][Full Text] [Related]
31. [Evaluation of an immunoassay for calcitonin].
Sylla Niang M; Lombardo F; Schlumberger M; Bidart JM
Dakar Med; 2008; 53(1):76-83. PubMed ID: 19102121
[TBL] [Abstract][Full Text] [Related]
32. Medullary thyroid carcinoma: a 20-year experience from a centre in South India.
Finny P; Jacob JJ; Thomas N; Philip J; Rajarathnam S; Oommen R; Nair A; Seshadri MS
ANZ J Surg; 2007 Mar; 77(3):130-4. PubMed ID: 17305985
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and management of medullary thyroid carcinoma.
Massoll N; Mazzaferri EL
Clin Lab Med; 2004 Mar; 24(1):49-83. PubMed ID: 15157557
[TBL] [Abstract][Full Text] [Related]
34. Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination.
Pfragner R; Skofitsch G; Höger H; Jech M; Rinner B; Siegl V; Niederle B; Gnant M; Friedl J; Stift A
Anticancer Res; 2005; 25(6B):4225-30. PubMed ID: 16309220
[TBL] [Abstract][Full Text] [Related]
35. Anticancer activity of novel extracts from Cautleya gracilis (Smith) Dandy: apoptosis in human medullary thyroid carcinoma cells.
Li Z; Sturm S; Svejda B; Höger H; Schraml E; Ingolic E; Siegl V; Stuppner H; Pfragner R
Anticancer Res; 2008; 28(5A):2705-13. PubMed ID: 19035299
[TBL] [Abstract][Full Text] [Related]
36. Update on medullary thyroid cancer.
Hu MI; Ying AK; Jimenez C
Endocrinol Metab Clin North Am; 2014 Jun; 43(2):423-42. PubMed ID: 24891170
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies.
Vitale G; Lupoli G; Guarrasi R; Colao A; Dicitore A; Gaudenzi G; Misso G; Castellano M; Addeo R; Facchini G; Del Prete S; Caraglia M
J Clin Endocrinol Metab; 2013 Oct; 98(10):E1567-74. PubMed ID: 23884781
[TBL] [Abstract][Full Text] [Related]
38. Characterisation of thyroid medullary carcinoma TT cell line.
Zabel M; Grzeszkowiak J
Histol Histopathol; 1997 Jan; 12(1):283-9. PubMed ID: 9046062
[TBL] [Abstract][Full Text] [Related]
39. Medullary carcinoma of the thyroid with serotonin production and carcinoid-like syndrome.
Hocevar M; Bergant D; Auersperg M; Golouh R
Eur J Surg Oncol; 2001 Mar; 27(2):219-22. PubMed ID: 11289766
[No Abstract] [Full Text] [Related]
40. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma.
Vitale G; Tagliaferri P; Caraglia M; Rampone E; Ciccarelli A; Bianco AR; Abbruzzese A; Lupoli G
J Clin Endocrinol Metab; 2000 Mar; 85(3):983-8. PubMed ID: 10720027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
